La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ocugen Crescita futura

Future criteri di controllo 2/6

Si prevede che Ocugen aumenterà gli utili e i ricavi rispettivamente del 36.2% e 59.8% all'anno, mentre si prevede che l'EPS crescerà del 57.6% all'anno.

Informazioni chiave

36.2%

Tasso di crescita degli utili

57.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.3%
Tasso di crescita dei ricavi	59.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	09 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:OCGN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	21	-46	N/A	N/A	1
12/31/2025	N/A	-50	N/A	N/A	3
12/31/2024	3	-50	N/A	N/A	3
6/30/2024	7	-45	-54	-46	N/A
3/31/2024	7	-58	-66	-54	N/A
12/31/2023	6	-63	-73	-62	N/A
9/30/2023	3	-82	-77	-68	N/A
6/30/2023	3	-90	-76	-68	N/A
3/31/2023	3	-86	-69	-63	N/A
12/31/2022	2	-87	-65	-60	N/A
9/30/2022	N/A	-74	-59	-56	N/A
6/30/2022	N/A	-63	-52	-50	N/A
3/31/2022	N/A	-69	-59	-58	N/A
12/31/2021	N/A	-58	-49	-48	N/A
9/30/2021	N/A	-48	-41	-39	N/A
6/30/2021	N/A	-47	-35	-34	N/A
3/31/2021	0	-38	-16	-15	N/A
12/31/2020	0	-34	-15	-15	N/A
6/30/2020	0	-30	-19	-19	N/A
3/31/2020	N/A	-18	-19	-19	N/A
12/31/2019	N/A	-20	-17	-17	N/A
9/30/2019	N/A	-39	-11	-11	N/A
6/30/2019	N/A	-18	-12	-12	N/A
3/31/2019	N/A	-19	-12	-12	N/A
12/31/2018	N/A	-18	-12	-12	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che OCGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che OCGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che OCGN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di OCGN ( 59.8% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di OCGN ( 59.8% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di OCGN è previsto essere elevato tra 3 anni

Ocugen Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates increase by 340%

Price target increased by 11% to US$7.00

Price target increased by 19% to US$6.33

Price target increased by 13% to US$4.50

Forecast to breakeven in 2026

Price target decreased by 17% to US$4.00

Recent updates

Consensus revenue estimates increase by 340%

Price target increased by 11% to US$7.00

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

New minor risk - Shareholder dilution

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy

Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

New major risk - Share price stability

Price target increased by 19% to US$6.33

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

New minor risk - Share price stability

Price target increased by 13% to US$4.50

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Insufficient new directors

Forecast to breakeven in 2026

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Price target decreased by 17% to US$4.00

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Price target decreased by 19% to US$3.90

Independent Director recently bought US$100k worth of stock

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Co-Founder exercised options and sold US$75k worth of stock

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Co-Founder notifies of intention to sell stock

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Co-Founder notifies of intention to sell stock

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Co-Founder exercised options and sold US$115k worth of stock

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen announces peer-reviewed publication on COVID-19 vaccine

Ocugen, Inc. Announces Board Changes

Price target decreased to US$7.00

Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout

Consensus forecasts updated

No longer forecast to breakeven

Consensus forecasts updated